Business Description
Beijing Konruns Pharmaceutical Co Ltd
ISIN : CNE1000036K3
Share Class Description:
SHSE:603590: Class ACompare
Compare
Traded in other countries / regions
603590.China IPO Date
2018-08-27Description
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, and is oriented to clinical needs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.95 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.07 | |||||
| Debt-to-EBITDA | 2.56 | |||||
| Interest Coverage | 18.94 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 6.06 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5 | |||||
| 3-Year EBITDA Growth Rate | -10.5 | |||||
| 3-Year EPS without NRI Growth Rate | -5.2 | |||||
| 3-Year FCF Growth Rate | 132.5 | |||||
| 3-Year Book Growth Rate | -0.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 30.23 | |||||
| Future 3-5Y Total Revenue Growth Rate | 19.42 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.15 | |||||
| 9-Day RSI | 61.26 | |||||
| 14-Day RSI | 58.83 | |||||
| 6-1 Month Momentum % | -15.26 | |||||
| 12-1 Month Momentum % | -41.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.55 | |||||
| Quick Ratio | 3.36 | |||||
| Cash Ratio | 2 | |||||
| Days Inventory | 207.28 | |||||
| Days Sales Outstanding | 118.52 | |||||
| Days Payable | 316.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.19 | |||||
| Dividend Payout Ratio | 0.38 | |||||
| 3-Year Dividend Growth Rate | -26.3 | |||||
| Forward Dividend Yield % | 1.19 | |||||
| 5-Year Yield-on-Cost % | 1.19 | |||||
| Shareholder Yield % | -0.95 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 88.59 | |||||
| Operating Margin % | 12.4 | |||||
| Net Margin % | 13.56 | |||||
| FCF Margin % | 5.74 | |||||
| ROE % | 3.66 | |||||
| ROA % | 2.97 | |||||
| ROIC % | 6.49 | |||||
| ROC (Joel Greenblatt) % | 12.32 | |||||
| ROCE % | 2.38 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.66 | |||||
| Forward PE Ratio | 18.08 | |||||
| PE Ratio without NRI | 31.59 | |||||
| Shiller PE Ratio | 14.61 | |||||
| Price-to-Owner-Earnings | 99.89 | |||||
| PS Ratio | 4.66 | |||||
| PB Ratio | 1.26 | |||||
| Price-to-Tangible-Book | 1.96 | |||||
| Price-to-Free-Cash-Flow | 82.29 | |||||
| Price-to-Operating-Cash-Flow | 24.15 | |||||
| EV-to-EBIT | 42.66 | |||||
| EV-to-EBITDA | 42.66 | |||||
| EV-to-Revenue | 4.27 | |||||
| EV-to-FCF | 70.53 | |||||
| Price-to-Projected-FCF | 1.18 | |||||
| Price-to-Graham-Number | 1.66 | |||||
| Price-to-Net-Current-Asset-Value | 11.81 | |||||
| Earnings Yield (Greenblatt) % | 2.34 | |||||
| FCF Yield % | 1.2 | |||||
| Forward Rate of Return (Yacktman) % | -13.39 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beijing Konruns Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 846.287 | ||
| EPS (TTM) (Â¥) | 0.729 | ||
| Beta | 0.98 | ||
| Volatility % | 34.74 | ||
| 14-Day RSI | 58.83 | ||
| 14-Day ATR (Â¥) | 0.753573 | ||
| 20-Day SMA (Â¥) | 24.64 | ||
| 12-1 Month Momentum % | -41.44 | ||
| 52-Week Range (Â¥) | 20.07 - 41.38 | ||
| Shares Outstanding (Mil) | 160 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beijing Konruns Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beijing Konruns Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Beijing Konruns Pharmaceutical Co Ltd Frequently Asked Questions
What is Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590)'s stock price today?
The current price of SHSE:603590 is ¥25.27. The 52 week high of SHSE:603590 is ¥41.38 and 52 week low is ¥20.07.
When is next earnings date of Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590)?
The next earnings date of Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590) is .
Does Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590) pay dividends? If so, how much?
The Dividend Yield %  of Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590) is 1.19% (As of Today), Highest Dividend Payout Ratio of Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590) was 0.53. The lowest was 0.25. And the median was 0.48. The  Forward Dividend Yield % of Beijing Konruns Pharmaceutical Co Ltd(SHSE:603590) is 1.19%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers